Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?

Visual Hallucinations in the Psychosis Spectrum and Comparative Information From Neurodegenerative Disorders and Eye Disease

(2014) Flavie Waters et al.   SCHIZOPHRENIA BULLETIN

Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on   Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations

(2013) M. Kometer et al.   JOURNAL OF NEUROSCIENCE

The Neurodynamic Organization of Modality-Dependent Hallucinations

(2012) Renaud Jardri et al.   CEREBRAL CORTEX

Prediction of Psilocybin Response in Healthy Volunteers

(2012) Erich Studerus et al.   PLoS One

Ketamine Decreases Resting State Functional Network Connectivity in Healthy Subjects: Implications for Antidepressant Drug Action

(2012) Milan Scheidegger et al.   PLoS One

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

(2012) R. L. Carhart-Harris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of serotonin receptors in the action of atypical antipsychotic drugs

(2011) HY Meltzer et al.   CURRENT OPINION IN PHARMACOLOGY

Childhood Onset Schizophrenia: High Rate of Visual Hallucinations

(2011) Christopher N. David et al.   JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY

Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors

(2011) Graham M Pitcher et al.   NATURE MEDICINE

Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors

(2011) Laura Albizu et al.   NEUROPHARMACOLOGY

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

(2011) Matthew J. Fell et al.   NEUROPHARMACOLOGY

From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment

(2011) Bita Moghaddam et al.   NEUROPSYCHOPHARMACOLOGY

Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment

(2011) Ming Li et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Evolutionary constraints on visual cortex architecture from the dynamics of hallucinations

(2011) T. C. Butler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Is the Acute NMDA Receptor Hypofunction a Valid Model of Schizophrenia?

(2011) A. Adell et al.   SCHIZOPHRENIA BULLETIN

Auditory verbal hallucinations and cognitive functioning in healthy individuals

(2011) Kirstin Daalman et al.   SCHIZOPHRENIA RESEARCH

Regulation of the dopamine transporter

(2010) Kyle C. Schmitt et al.   Annals of the New York Academy of Sciences

The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations

(2010) Michael Kometer et al.   BIOLOGICAL PSYCHIATRY

The effect of dopamine receptor blockade in the rodent nucleus accumbens on local field potential oscillations and motor activity in response to ketamine

(2010) Pawel Matulewicz et al.   BRAIN RESEARCH

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

(2010) Erich Studerus et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Increased 5-HT2Areceptors in the temporal cortex of parkinsonian patients with visual hallucinations

(2010) Philippe Huot et al.   MOVEMENT DISORDERS

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

(2010) Franz X. Vollenweider et al.   NATURE REVIEWS NEUROSCIENCE

Future classification of psychotic disorders

(2009) Wolfgang Gaebel et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Schizophrenia

(2009) Jim van Os et al.   LANCET

Glutamatergic (N-Methyl-D-aspartate Receptor) Hypofrontality in Schizophrenia: Too Little Juice or a Miswired Brain?

(2009) G. J. Marek et al.   MOLECULAR PHARMACOLOGY

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Dopamine D2Highreceptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil

(2009) Philip Seeman et al.   SYNAPSE

Psychedelics and schizophrenia

(2009) Javier González-Maeso et al.   TRENDS IN NEUROSCIENCES

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET

Identification of a serotonin/glutamate receptor complex implicated in psychosis

(2008) Javier González-Maeso et al.   NATURE

Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia

(2008) Paul C. Fletcher et al.   NATURE REVIEWS NEUROSCIENCE

Prefrontal cortex–nucleus accumbens interaction: In vivo modulation by dopamine and glutamate in the prefrontal cortex

(2008) Alberto Del Arco et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines

(2008) J. C. Winter   PSYCHOPHARMACOLOGY

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis

(2008) Karsten Heekeren et al.   PSYCHOPHARMACOLOGY

Realistic expectations of prepulse inhibition in translational models for schizophrenia research

(2008) Neal R. Swerdlow et al.   PSYCHOPHARMACOLOGY

Serotonin research: contributions to understanding psychoses

(2008) M GEYER et al.   TRENDS IN PHARMACOLOGICAL SCIENCES